| Name | ondansetron hydrochloride |
|---|---|
| Synonyms |
ondansteron hydrochloride dihydrate
4H-Cbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-, monohydrochloride (9CI) 4H-CARBAZOL-4-ONE,1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-,HYDROCHLORIDE (1:1) thyl)-,hydrochloride,hydrate(1:1:2) 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride 4h-cbazol-4-one,1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)me 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-cbazol-4-one 1,2,3,9-Tetrahydro-9-Methyl-3-[(2-Methyl-1H-iMidazol-1-yl)Methyl]-4H-cbazol-4-one Hydochloride 9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4h-carbazol-4-onhydrochlorid 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-cbazol-4-one hydrochloride dihydrate 9-Methyl-3-((2-Methyl-1H-iMidazol-1-yl)Methyl)-2,3-dihydro-1H-cbazol-4(9H)-one hydrochloride 4H-carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-, monohydrochloride Ondansetron hydrochloride, 10 mM in DMSO Ondansetron (hydrochloride) ONDANSETRON HCL DIHYDRATE IMP. E (EP): 1H-IMIDAZOLE, CRM STANDARD ONDANSETRON HCL Ondansetron hydrochloride (Zofran) 4H-Cbazol-4-one,1,2,3,9-tetrahydro-9-Methyl-3-[(2-Methyl-1H-iMidazol-1-yl)Methyl]-,hydrochloride (1:1) OEA EMeset Zofran ONDANSETRONE HYDROCHLORIDE [3H]-Ondansetron hydrochloride Osetron Ondansetron hydrochloride, 5-HT3 rector antagonist ODANSETRON HYDROCHLORIDE DIHYDRATE sn307 Poxetine IMpurity A Ondansetron HydrochlorideQ: What is Ondansetron Hydrochloride Q: What is the CAS Number of Ondansetron Hydrochloride Q: What is the storage condition of Ondansetron Hydrochloride UNII:2999F27MAD (R)-Ondansetron Hydrochloride Dihydrate Ondansetron hydrochloride 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-cbazol-4-one hydrochloride 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one LSUREMONOETHANOLAMID Ondansetron HCl OEA,oleoylethanolamide N-(Hydroxyethyl)oleamide 38032F [3H]-Oleoylethanolamide Ondansetron HCl 38032F) oleic acid ethanolamide ONDANSETRON HCL DIHYDRATE Ondansetron HCl (Zofran) Zophren 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-cbazol-4-one hydochloride dihydrate oleic monoethanolamide 38032 HCl Ondansetron hydrochloride - Bio-X ONDANSETRONHYDROCHLORIDE 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-cbazol-4-one hydrochloride oleic acid-N-monoethanolamide N-(2-Hydroxyethyl)oleamide Ondasatrone Reference Standd Oleoylethanolamide Hydrochloride dihydrate 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-, hydrochloride (1:1) OdansetronHCldihydrate Oleyl monoethanolamide OLEAMIDE MEA 9-méthyl-3-[(2-méthyl-1H-imidazol-1-yl)méthyl]-1,2,3,9-tétrahydro-4H-carbazol-4-one chlorhydrate Zudan Oleoylmonoethanolamide 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride (1:1) |
| Description | Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.Target: 5- HT ReceptorIC50 Value: in vitro: 5-HT evoked transient inward currents (EC50 = 3.4 microM; Hill coefficient = 1.8) that were blocked by the 5-HT3 receptor antagonist ondansetron (IC50 = 103 pM) [1]. The 5-HT3A receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 microM) signal by 70% and at 3 nM it abolished the response [2].in vivo: Acute ondansetron administration at the lowest dose (0.1 mg/kg, IP) tested had no effect, while other doses (0.33 and 1 mg/kg, IP) produced improvements in auditory gating [3]. Different doses of ondansetron were injected intraperitoneally (i.p.) at fixed times during the day to determine both the sublethal (TD50) and lethal (LD50) doses, which were, respectively, 3.7 +/- 0.6 mg/kg and 4.6 +/- 0.5 mg/kg [4]. ondansetron (0.25-1.0 mg/kg, subcutaneously) given before the challenge dose of ethanol (2.4 g/kg, intraperitoneally) injection, significantly and dose dependently attenuated the expression of sensitization. In addition, ondansetron (1.0 mg/kg, subcutaneously) given before ethanol injection on days 1, 4, 7, and 10 significantly blocked the development (days 1, 4, 7, and 10), and expression (day 15) of sensitization to the locomotor stimulant effect of ethanol injection [5]. Toxicity: Ondansetron may be safe in lower doses used to prevent nausea and vomiting in radiation treatment or postoperatively. However, as there is a report that a lower dose of ondansetron prolonged the QT interval in healthy volunteers, this needs to be clarified by the FDA [6]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.27g/cm3 |
|---|---|
| Boiling Point | 546ºC at 760mmHg |
| Melting Point | 178.5-179.5ºC |
| Molecular Formula | C18H20ClN3O |
| Molecular Weight | 329.824 |
| Flash Point | 284ºC |
| Exact Mass | 329.129486 |
| PSA | 39.82000 |
| LogP | 3.93050 |
| Storage condition | −20°C |
| Water Solubility | H2O: >5 mg/mL |
| Hazard Codes | T: Toxic; |
|---|---|
| Risk Phrases | R25 |
| Safety Phrases | 45-37/39-26 |
| RIDADR | UN 2811 6 |
| WGK Germany | 3 |
| RTECS | FE6375500 |
| Packaging Group | II |
| Hazard Class | 6.1(a) |
| HS Code | 29339900 |
|
~90%
99614-01-4 |
| Literature: WO2005/37822 A1, ; Page/Page column 12 ; |
|
~78%
99614-01-4 |
| Literature: WO2005/37822 A1, ; Page/Page column 12 ; |
|
~93%
99614-01-4 |
| Literature: YUHAN CORPORATION Patent: WO2005/37822 A1, 2005 ; Location in patent: Page/Page column 12 ; |
| Precursor 4 | |
|---|---|
| DownStream 2 | |